Title:Quercetin-Decorated Curcumin Liposome Design for Cancer Therapy: In-Vitro and In-Vivo Studies
VOLUME: 14 ISSUE: 8
Author(s):V. Ravichandiran, K. Masilamani, B. Senthilnathan, A. Maheshwaran, Tin Wui Wong and Partha Roy*
Affiliation:National Institute of Pharmaceutical Education and Research, Kolkata, Faculty of Engineering Technology (Pharmaceutical), University Malaysia Pahang, Gambang-26300, Kuantan, Jaya College of Paramedical Sciences, CTH Road, Thiruninravur, Chennai--602 024, Tamil Nadu, CARISM Sastra University, Thanjavur, Tamilnadu, Non-Destructive Biomedical and Pharmaceutical Research Centre iPROMISE Universiti Teknologi MARA 42300 Puncak Alam Selangor, Department of Pharmaceutical Technology, Adamas University, Kolkata
Keywords:Curcumin, Dalton's ascites lymphoma, liposomes, quercetin, cancer, cytotoxicity.
Abstract:Background: Curcumin is a yellow polyphenolic chemopreventive agent isolated from the
rhizomes of Curcuma longa. It is approved as Generally Regarded as Safe by US FDA. Nonetheless,
its clinical success is limited due to its poor aqueous solubility, fast metabolism and short biological
half-life attributes.
Objective: Quercetin-decorated liposomes of curcumin (QCunp) are perceived to be able to overcome
these biopharmaceutical drawbacks.
Methods: Curcumin liposomes with/without quercetin were prepared by lipid hydration technique.
The liposomes were characterized for their particle size, zeta potential, surface morphology, drug
loading and release characteristics. The toxicity of the liposomes were evaluated in-vitro and their invivo
efficacy were tested against Dalton's ascites lymphoma in mice.
Results: Liposomes designed showed particle size of 261.8 ± 2.1 nm with a negative zeta potential of
-22.6±1.6 mV. Quercetin decorated liposomes were more effective in increasing the life span and
body weight of lymphoma inflicted mice compared to those without quercetin. Similarly, the presence
of quercetin also contributed to enhanced cytotoxicity of the liposomal formulation towards HT-29
cells and HCT-15 cells.
Conclusion: Newer liposomal design exhibited promising potential to emerge as alternative anticancer
therapeutics.
